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Obesity Epidemic 
Time to Wake Up 
Dr Noel CARUANA 
It is general~ accepted that obesity is a health hazard due to its association with 
a number of metabolic complications such as type 2 diabetes, dyslipidaemia and 
cardiovascular disease. We as clinicians have been trained to define obesity on the basis of 
weight in kilogrammes expressed over height in metres squared, the so called BMI (Body 
mass index) initial~ described by Quetelet way back in 1869. 
Indeed epidemiological studies have shown an increase in 
incidence of metabolic diseases with increasing BMl.l However 
despite this evidence many of us clinicians in our daily practice are 
often baffled by the differences in our patients; thus some patients 
who have considerable excess body fat show a normal metabolic 
risk profile whereas others who are moderately overweight show a 
whole range of metabolic complications such as type 2 Diabetes 
atherosclerosis and cardiovascular disease. 
This thought has led to a rethinking of the notion suggested 
in the 1940's by a French Physician Dr Jean Vague,2 whereby 
complications related to excess fat were related to where the fat 
was distributed rather than on the total amount per se. Thus 
android obesity or male obesity is considered to be a major risk 
factor for coronary heart disease and type 2 diabetes and their 
related mortalities.3 Gynoid obesity or the accumulation of fat in the 
gluteofemoral area, is not related to increased cardiovascular risk" 
Thus there is currently enough evidence to suggest that 
abdominal obesity is a major lisk factor which needs our serious 
consideration when we are assessing and managing an abdominally 
obese individual. 
Fat, what fat? 
As time goes by, an increasing proportion of our population is 
becoming more sedentary and is being habitually exposed to an 
energy rich and refined food which favours obeSity. It is a fact that 
although abdominal obeSity has a definite genetic basis, obesity will 
only develop in the presence of an energy rich environment. 
Anthropometric variables such as waist to hip ratios and 
abdominal circumference, when compared to measurements 
obtained with sophisticated imaging techniques such as magnetic 
resonance imaging (MRl) and Computed tomography (CT) have 
shown that a simple measurement of waist circumference was 
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the best anthropometric correlate of the level of visceral adipose 
tissue. 5 
Upper body obeSity develops from adiposity in subcutaneous 
and intra-abdominal compartments. Intra-abdominal fat (visceral 
fat) is defined as the fat located around the viscera, within the 
peritoneum, the dorsal surface of the intestines and the surface 
of the kidneys. It is important to realise that BMI is not a reliable 
indicator of the extent of intra- abdominal adiposity, and two men 
with a similar BMI may have different distribution of visceral fat 
and also different cardiometabolic risk 
Visceral Obesity and metabolic 
complications 
A number of prospective studies have shown that abdominal 
obeSity is a major risk factor for the onset of type 2 diabetes which in 
turn increases the risk of retinopathy, neuropathy, nephropathy and 
atherogenic macrovascular disease3 Obese individuals with visceral 
adipose tissue distribution are more likely to have high triglyceride 
and low levels of high density lipoprotein. Despite this, viscerally 
obese individuals tend to have low denSity lipoprotein(LDL) levels 
in the normal range, yet have increased levels of apolipoprtotein B 
(a marker of the concentration of atherogenic lipoproteins)6 This 
observation indicates that doctors need to look carefully at results 
of cholesterol and LDL levels and interpret these in the context of 
whether the patient has visceral adiposity or not. 
A prospective study of a group of asymptomatic middle aged 
men, who were followed up over a period of five years, indicated 
that a group of metabolic abnormalities found in viscerally obese 
men was associated with a significant increase in coronary 
heart disease risk This group of deranged metabolic parameters 
included: fasting hyperinsulinaemia, increased small dense LDL 
particles and increased apolipoprotein B concentration, even in 
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the absence of type 2 diabetes was seen to be associated with a 
20 times increase in risk of developing ischaemic heart disease in 
a five year follow up period in this group of men. 7 
The metabolic syndrome 
The prognostic Significance of increased waist circumference 
has been incorporated in the criteria used to identify persons with 
features of the metabolic syndrome. In the USA, the National 
Cholesterol Education Program- adult treatment panel III (NCEP-
ATP) drawn criteria dating from 2001 include i) waist circumference 
(> 102cm for men and >88cm for women) iO elevated TG, iiO Low 
HDL cholesterol, iv) high BP and v) high FPG. The International 
Diabetes Federation (lDF) has made the presence of abdominal 
obesity a requirement for the diagnosis of metabolic syndrome 
along with any other 3 criteria from the NCEP-ATP Ill. Indeed 
the lDF sets lower cut-off points (men/women) for abdominal 
circumference, >94/ >80 for European area,> 90/>80 for South 
Asian and >85/ >90 for Japanese persons 8 
How to identify high risk individuals 
with visceral adiposity? 
It is indeed difficult in our practice, to use costly MRI or 
CT to determine if an individual who is obese, has visceral 
adipOSity, as this would be too costly and involves irradiating 
the patient. We have come to realise that BMI does not provide 
a reliable indication of the extent of intra-abdominal adipOSity. 
Fortunately anthropometric studies have shown that abdominal 
circumference (measured at mid- distance between bottom of 
rib cage and iliac crest) not only prediCts presence of visceral adipose 
accumulation but also allows follow up over time. It is also difficult 
in practice to determine fasting insulin levels and apolipoprotein 
levels; however it has been shown that the plasma triglyceride 
concentration measured in the morning after a 12hour fast is 
a reliable indicator of small dense LDL6 9 
SenSitivity and specific ity of abdominal circumference and 
triglyceride levels as predictors of hyperinsulinaemia and increased 
apolipoprotein B have been tested in an analysis of a sample of men 
aged 30 and 65 years ID This analysis has shown that a cut-off point 
of90cm waist circumference provides the best discriminative ability 
to distinguish men with hyperinsulinaemia and high apolipoprotein 
B levels from those with normal levels. A cut off level of 2mmoVl 
fasting triglyceride concentration is the best predictor of the 
presence of small, dense LDL. Using these parameters one can 
identify correctly 80% of individuals, with only 10% being missed ID 
These results highlight the importance of the measurement and 
correct interpretation of waist circumference and fasting TG 
concentration - The Hypertriglyceridaemic waist. 
Short overview of the adipokines 
Visceral obeSity promotes increased secretion of a range of 
metabolites and biologically active substances from fat tissues, 
including free fatty acids (FFA) , inflammatory mediators e.g. 
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Tumor necrosis factor (TNF) and interleukin-6(IL-6), plasminogen 
activator inhibitor-l (PAl-I) and C- reactive protein. 
Atherosclerosis has been shown to have an inflammatory 
component and adipokines may be involved in atherogenesis in 
abdominally obese individuals l 2 IL-2 is a systemic adipokine, 
and it impairs insulin sensitivity and is also a major determinant 
of hepatiC production of C-reactive protein (CRP). Thus levels 
of CRP are elevated in persons who have abdominal obeSity 
and conversely individuals with elevated CRP tend to have intra 
abdominal adipositylJ 
Adiponectin a cardioprotective adipokine is found to be 
decreased in abdominally obese individuals I I. Chronic pancreatic 
exposure to FFA disrupts-cell function and acute exposure 
of skeletal muscle to elevated levels of FFA induces insulin 
resistance I 0.1 5 Adiponectin has also been shown to improve insulin 
sensitivity and glycaemiC control and its levels correlate positively 
with levels of HDL-chol and inversely with TG or PAI- 116 
Interventions in the management of Obesity 
Treating obeSity is a big challenge and often the outcome 
is unsuccessful or partially so. Current management guidelines 
promote the use of lifestyle interventions, primarily diet and 
exercise, as these have the potential to improve both cardiac and 
metabolic risk factors. These may be coupled with direct treatment 
of individual complications of obesity such as dyslipidaemia, 
diabetes and hypertension. However, sadly enough, lifestyle 
interventions are often unsuccessful, due in part to lack of patient 
compliance. Given this scenario pharmacotherapy is justified to 
control an elevated cardiometabolic risk. 
Recent research has determined that over activity of the 
endocannabinoid system acting via the CBI receptor is an important 
factor in the pathogenesis of cardiometabolic riskll CBI receptors 
have been identified in many organs including the adipose 
tissue, liver, skeletal muscle and centrally in the hypo thalamus. 
Endogenous cannabinoids are derivatives of arachidonic acid 
and stimulate CBI receptors to cause a number of metabolic 
effects notably; decreased glucose uptake by skeletal muscle, 
hyperphagia, increased lipogenesis both in liver and adipose tissue 
and decreased adiponectin production l 7 . Thus any substance 
which blocks CBI receptors would counter act these effects. 
Rimonabant has been developed as the firs t CBI receptor 
blocker and has undergone extensive evaluation in patients with 
obesity and other metabolic disorders in the Rimonabant in ObeSity 
(RIO) trial programme. This comprised four 1-2 year Phase III 
trials (RIO-Lipids I8, RlO-Europe I9, RIO North America2o, and 
RIO Diabetes21) in over 6600 overweight/obese patients on a mild 
hypo-caloric diet (reduced by 600 kcal daily) assessing the efficacy 
and safety of rimonabant 5 and 20mg /day. 
RIO-Europe studied a group of obese (BMl >30kg/m2 )or 
overweight(BMl> 27 kg/m2 ) patients with a minimum of one 
cardiovascular risk factor such as treated or untreated dyslipidaemia 
or hypertenSion while the RIO-Lipids trial observed obese 
or overweight patients with untreated dyslipidaemia such as 
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elevated triglycerides or total cholesterol:HDL ratio. In the RIO 
Diabetes, a group of 1047 diabetic patients (BMI2 7-40) receiving 
metfonnin or sulphonylurea were followed-up to evaluate the 
effect of rimonabant not only on reduction of weight and waist 
circumference but also on HbAIC.In the RIO NA trial patients were 
re randomised after a year to carry on treatment with rimonabant or 
receive placebo. In all trials, after 1 year, rimonabant significantly 
(P<O.OOl) reduced weight and waist circumference to a greater 
extent than placebo; mean weight loss was -6.5kg and a decrease 
in abdominal circumference of -6. 4cm was observed (pooled data 
RIO-NA, RIO-EU and RIO-Lipids). The same dose of rimonabant 
also effected a reduction in triglyceride level and increase in HDL 
levels. In the RIO Diabetes study, a Significantly greater percentage 
of patients also achieved the clinically Significant end-point of 
HbAlc<6.5% as compared to those receiving placebo (42.9% 
vs 20.8%; p<O.OOl). Rimonabant 20mg daily also resulted in an 
increase of plasma adiponectin of 57. 7% (repeated measurements 
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